Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Chordoma Clinical Trials

A listing of Chordoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (12) clinical trials

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

PRIMARY OBJECTIVES: I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. II. To evaluate the overall response rate (ORR) in patients with gestational trophoblastic tumors treated with …

Phase

Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors

This is a Phase 1/1b, open-label study, which consists of dose escalation parts (Part A) followed by expansion cohorts (Part B) for both single agent BCA101 and combination BCA101 plus pembrolizumab. The study population in dose escalation (Part A) of single agent BCA101 consists of subjects with EGFR-driven advanced solid …

Phase

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent Advanced or Metastatic Chordoma

PRIMARY OBJECTIVES: I. To assess the safety profile of nivolumab alone and nivolumab in combination with stereotactic radiosurgery to treat patients with recurrent or advanced chordoma. SECONDARY OBJECTIVES: I. To evaluate toxicity and tolerability of nivolumab alone and nivolumab in combination with stereotactic radiosurgery. II. To estimate growth modulation index …

Phase

Nivolumab (Opdivo ) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

The primary objective of this study is to investigate the maximum tolerated dose of ABI-009, an mTOR inhibitor, when given sequentially with nivolumab in advanced Ewing's sarcoma, PEComa, epithelioid sarcoma, desmoid tumor, chordoma, non-small cell lung cancer, small cell lung cancer, urethelial carcinoma, melanoma, renal cell carcinoma, squamous cell carcinoma …

Phase

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug or drug combination to learn whether the drug or drug combination works in treating a specific disease. "Investigational" means that the drug combination is being studied. The names of the study …

Phase

Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease

International, multicenter, comparative, open-label, parallel-group, mixed Observational-Randomized Controlled Trial. All the patients, who are candidate for the study will receive full information on the characteristics, potential effectiveness and side effects of the two alternatives treatments: radiotherapy (RT) and surgical treatment Eligible patients will be asked to be randomized in order …

Phase N/A

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

PRIMARY OBJECTIVES: I. To assess the clinical benefit of the combination of nivolumab and relatlimab in patients with advanced chordomas by objective response rate (ORR). SECONDARY OBJECTIVES: I. Ascertain the safety of nivolumab in combination with relatlimab in subjects with metastatic or locally advanced/unresectable chordoma by the frequency of adverse …

Phase

Children and Adults With Chordoma

Background Chordomas are a rare tumor with an incidence of 325 new cases per year in the United States. Pediatric chordomas are very rare and comprise only 5% of all chordoma cases. The standard therapy for localized primary or recurrent chordomas is surgical resection. However, complete surgical resection is often …

Phase N/A

Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers

Background There are more than 130 identified primary tumors of the central nervous system (CNS). Most have an annual incidence of less than 1000 in the United States. Given the rarity of each of the tumors listed above, there is a paucity of proven therapies. Most of these neoplasms are …

Phase

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced Unresectable or Metastatic Chordoma

For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. …

Phase